Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics' (CTNM) quarterly Total Non-Current Liabilities came in at $14.8 million in Q4 2024, up 164.32% year-on-year from $5.6 million in Q1 2024, and up 154.58% quarter-over-quarter from $5.8 million in Q3 2024.

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Contineum Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $14.8 million for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities rose 164.32% year-over-year to $14.8 million in Q4 2024; TTM through Dec 2024 was $14.8 million, a 164.32% increase from a year earlier, with the FY2024 full-year figure at $14.8 million, up 164.32% from the prior year.
  • Total Non-Current Liabilities grew to $14.8 million in Q4 2024 per CTNM's latest filing, from $5.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $14.8 million in Q4 2024 and bottomed at $3.9 million in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Contineum Therapeutics 536.56 Mn 536.56 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 14.78 Mn
Sep 30, 2024 5.81 Mn
Jun 30, 2024 3.85 Mn
Mar 31, 2024 6.35 Mn
Dec 31, 2023 5.59 Mn